It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Earlier this year, an article in the journal Biosecurity and Bioterrorism, analyzing government biodefense spending from 2001 to 2008, stated that $49.66 billion has been allocated for civilian biodefense. (separate from bioshield)According to microbiologist and longtime biodefense critic Richard Ebright of Rutgers University, actual spending is even higher, amounting to $57 billion.
In 2005, he and 757 other microbiologists sent a stinging open letter to Elias Zerhouni, director of the National Institutes of Health, protesting the government’s preoccupation with “priority pathogens” -- germs such as anthrax that could be used in a bioweapons attack. But Zerhouni and Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, would have none of it. In a letter published in the journal Science, they disagreed: “The United States has experienced an anthrax attack, and security experts repeatedly express concern that future attacks with biological weapons are likely, if not inevitable.”
Dr. Fauci knew VaxGen because the company had a promising AIDS vaccine that his agency had funded over several years. In 2003, however, the AIDS vaccine failed important clinical trials. In the meantime, VaxGen was busy reinventing itself as a biodefense company with a next-generation anthrax vaccine candidate.
Dr. Fauci's agency awarded $100 million in two funding rounds to VaxGen and about $80 million in two rounds to its main rival, Avecia Group PLC, a United Kingdom biotechnology company. The idea was to get them prepared to compete for a big federal contract to deliver a new anthrax vaccine to the national stockpile.
One of VaxGen's rivals, BioPort Corp., of Lansing, Mich., cried foul. The bidding specifically excluded any makers of the existing older-generation vaccine, of which there was just one, BioPort. The company swung into action, hiring publicists and lobbyists. Eventually, BioPort received a $122 million contract to *supply the older vaccine, which is approved by the Food and Drug Administration, to the U.S. stockpile.
At a House government reform committee hearing last month, Rep. Chris Cannon, a Utah Republican, grilled Dr. Fauci: "So now we've got a small company [VaxGen] failing to perform…We have an experimental technology to deal with a disease that we've already been attacked with…We don't have a stockpile, even though my understanding is, we have a company that has an FDA-approved vaccine for anthrax. Is that a fair statement of where we are?"
Since the 2001 terrorist attacks, the United States government has allocated nearly $50 billion to address the threat of biological weapons. U.S. funding for bioweapons-related activities focuses primarily on research for and acquisition of medicines for defense. Funding also goes toward stockpiling protective equipment, increased surveillance and detection of biological agents, and improving state and hospital preparedness. The increase in this type of funding is mainly for Project BioShield. Significant funding also goes to Biomedical Advanced Research and Development Authority (BARDA), part of HHS. Funding for activities aimed at prevention has more than doubled 2007 and is distributed to 11 federal agencies. Efforts toward cooperative international action are part of the project.
The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (PAHPAIA), signed into law on 24 June 2019, reauthorized Project BioShield’s Special Reserve Fund and authorized 10-year funding for product development.
• Amends the Public Health Service Act to allow the Director of the NIH to act through the Director of the National Institute of Allergy and Infectious Diseases (NIAID) to provide grants for the modernization and construction of research facilities. Increases the Federal share of such NIAID-funded projects.
Top U.S. scientist and research pioneer Dr. Judy Mikovits said she cooperated with the FBI during an investigation of Dr. Anthony Fauci and the National Institute of Health, alleging Fauci was a workplace tyrant who was under investigation for swiping scientific research, covering up tainted vaccines, doling out lucrative federal grants to feckless cronies and much more
The Leadership Council is comprised of:
Dr. Margaret Chan, Director General of WHO;
Dr. Anthony S. Fauci, Director of NIAID, part of the National Institutes of Health;
Mr. Anthony Lake, Executive Director for UNICEF;
Ms. Joy Phumaphi, Chair of the International Advisory Committee and Executive Secretary, African Leaders Malaria Alliance
Dr. Tachi Yamada, President of Global Health at the Bill & Melinda Gates Foundation;
“Back in 2014, the Obama administration prohibited the U.S. from giving money to any laboratory, including in the U.S., that was fooling around with these viruses. Prohibited. Despite that, Dr. Fauci gave $3.7 million to the Wuhan laboratory. And then even after the State Department issued reports about how unsafe that laboratory was, and how suspicious they were in the way they were developing a virus that could be transmitted to humans, we never pulled that money.”
originally posted by: Fallingdown
"Dr. Fauci knew VaxGen because the company had a promising AIDS vaccine that his agency had funded over several years. In 2003, however, the AIDS vaccine failed important clinical trials. In the meantime, VaxGen was busy reinventing itself as a biodefense company with a next-generation anthrax vaccine candidate."
So Fauci worked with VenGex during another one of his cash cow we’re all going to die if moments IE the HIV crisis. (One that he has basically lost all interest in. I assume it’s not profitable enough)